Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Enphase Energy Inc (ENPH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Enphase Energy Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Enphase Energy Inc trades at $44.05 (market cap $5.91B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 6.7× Enphase Energy Inc's market cap, and Enphase Energy Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | ENPH | |
|---|---|---|
Market Cap | $39.89B | $5.91B |
Sector | Health | Technology |
52-Week High | $491.22 | $72.33 |
52-Week Low | $278.09 | $26.12 |
Enterprise Value | $38.15B | $5.56B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
ENPH trades at $44.83, down 0.13% with a bearish technical signal. Recent earnings beats (Q1 2026 EPS $0.47 vs. $0.43 expected) contrast with declining revenue trends (2025: $1.47B vs. 2023 peak $2.3B). Analyst consensus is mixed (40% Buy, 51% Hold) with a $42.79 price target below current levels. News highlights product launches like IQ9N microinverters and Open Compute Project membership, aiming to leverage AI data center demand.
Outlook remains cautious due to revenue volatility and high valuation (P/E 44.39). Opportunities exist in new product adoption and regulatory tailwinds (FCC inverter import ban proposal, Reuters June 2026), but risks include solar sector competition and execution challenges. Institutional sentiment is neutral with modest net cash flow of $10.20M in 2025.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Enphase Energy Inc
Enphase Energy is a global energy technology company. The company delivers smart, easy-to-use solutions that manage solar generation, storage, and communication on one platform. The company's microinverter technology primarily serves the rooftop solar market and produces a fully integrated solar-plus-storage solution. Geographically, it derives a majority of revenue from the United States.
Read more on ENPH →
